Bromodomain inhibitor i-BET858 triggers a unique transcriptional response coupled to enhanced DNA damage, cell cycle arrest and apoptosis in high-grade ovarian carcinoma cells

Abstract Background Ovarian cancer has a specific unmet clinical need, with a persistently poor 5-year survival rate observed in women with advanced stage disease warranting continued efforts to develop new treatment options. The amplification of BRD4 in a significant subset of high-grade serous ova...

Cijeli opis

Bibliografski detalji

Glavni autori:	Marcos Quintela, David W. James, Agne Pociute, Lydia Powell, Kadie Edwards, Zoe Coombes, Jetzabel Garcia, Neil Garton, Nagindra Das, Kerryn Lutchman-Singh, Lavinia Margarit, Amy L. Beynon, Inmaculada Rioja, Rab K. Prinjha, Nicola R. Harker, Deyarina Gonzalez, R. Steven Conlan, Lewis W. Francis
Format:	Artigo
Jezik:	Inglês
Izdano:	BMC 2023-04-01
Serija:	Clinical Epigenetics
Teme:	Ovarian cancer BETi Advanced therapeutics Drug development i-BET858
Online pristup:	https://doi.org/10.1186/s13148-023-01477-x
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!